Plain-English translation of NCT06147635 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 2 โ Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether tributyrin, a food supplement, can help prevent serious complications in people who have just been diagnosed with acute pancreatitis (sudden pancreas inflammation). Researchers believe this supplement may help protect your gut and reduce the risk of dangerous infections or organ failure that can happen in severe pancreatitis. Half of participants will receive the active supplement, and half will receive a placebo (inactive look-alike) to see if the medication actually makes a difference.
Acute pancreatitis is a serious condition that sends many people to the hospital, and about 1 in 5 patients develop life-threatening complications like organ failure or infections. Currently, there is no safe, early treatment available to prevent these serious problems. This medication is being studied because laboratory research suggests it may strengthen your gut barrier and reduce harmful inflammation, potentially stopping these dangerous complications before they start.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You would take the supplement three times daily as small granules for up to 14 days while you are being treated in the hospital for pancreatitis. Doctors will monitor you closely with blood tests and measurements to track your recovery. You won't know if you're taking the active supplement or the placebo, and neither will your doctors โ this helps ensure the results are fair and accurate.
AI-generated summary from trial data ยท Aug 27, 2026 ยท Not medical advice
Netherlands